Literature DB >> 30058145

Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.

Jaclyn Rosenthal1, Ammar S Naqvi2,3, Minjie Luo4, Gerald Wertheim4, Michele Paessler4, Andrei Thomas-Tikhonenko2,4, Susan R Rheingold5, Vinodh Pillai4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30058145     DOI： 10.1002/ajh.25235

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  16 in total

Review 1.  Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.

Authors:  Sisi Zheng; Mukta Asnani; Andrei Thomas-Tikhonenko
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

2.  A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).

Authors:  Erica Brivio; Franco Locatelli; Marta Lopez-Yurda; Andrea Malone; Cristina Díaz-de-Heredia; Bella Bielorai; Claudia Rossig; Vincent H J van der Velden; Anneke C J Ammerlaan; Adriana Thano; Inge M van der Sluis; Monique L den Boer; Ying Chen; Barbara Sleight; Benoit Brethon; Karsten Nysom; Lucie Sramkova; Ingrid Øra; Luciana Vinti; Christiane Chen-Santel; Christian Michel Zwaan
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

3.  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Authors:  Vinodh Pillai; Kavitha Muralidharan; Wenzhao Meng; Asen Bagashev; Derek A Oldridge; Jaclyn Rosenthal; John Van Arnam; Jos J Melenhorst; Diwakar Mohan; Amanda M DiNofia; Minjie Luo; Sindhu Cherian; Jonathan R Fromm; Gerald Wertheim; Andrei Thomas-Tikhonenko; Michele Paessler; Carl H June; Eline T Luning Prak; Vijay G Bhoj; Stephan A Grupp; Shannon L Maude; Susan R Rheingold
Journal:  Blood Adv       Date:  2019-11-26

4.  Tuning the Antigen Density Requirement for CAR T-cell Activity.

Authors:  Robbie G Majzner; Skyler P Rietberg; Elena Sotillo; Rui Dong; Vipul T Vachharajani; Louai Labanieh; June H Myklebust; Meena Kadapakkam; Evan W Weber; Aidan M Tousley; Rebecca M Richards; Sabine Heitzeneder; Sang M Nguyen; Volker Wiebking; Johanna Theruvath; Rachel C Lynn; Peng Xu; Alexander R Dunn; Ronald D Vale; Crystal L Mackall
Journal:  Cancer Discov       Date:  2020-03-19       Impact factor: 39.397

5.  A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.

Authors:  Ranjan Upadhyay; Jonathan A Boiarsky; Gvantsa Pantsulaia; Judit Svensson-Arvelund; Matthew J Lin; Aleksandra Wroblewska; Sherry Bhalla; Nathalie Scholler; Adrian Bot; John M Rossi; Norah Sadek; Samir Parekh; Alessandro Lagana; Alessia Baccarini; Miriam Merad; Brian D Brown; Joshua D Brody
Journal:  Cancer Discov       Date:  2020-12-17       Impact factor: 39.397

Review 6.  Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.

Authors:  Lele Miao; Zhengchao Zhang; Zhijian Ren; Futian Tang; Yumin Li
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

7.  Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.

Authors:  Haibo Zhu; Haobin Deng; Juan Mu; Cuicui Lyu; Yanyu Jiang; Qi Deng
Journal:  Onco Targets Ther       Date:  2021-07-02       Impact factor: 4.147

Review 8.  Current Status of CAR T Cell Therapy for Leukemias.

Authors:  Katherine Harris; James L LaBelle; Michael R Bishop
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

Review 9.  Antigen Loss after Targeted Immunotherapy in Hematological Malignancies.

Authors:  Ting Zhou; Hao-Wei Wang
Journal:  Clin Lab Med       Date:  2021-07-02       Impact factor: 2.172

10.  CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum.

Authors:  Asen Bagashev; Elena Sotillo; Chih-Hang Anthony Tang; Kathryn L Black; Jessica Perazzelli; Steven H Seeholzer; Yair Argon; David M Barrett; Stephan A Grupp; Chih-Chi Andrew Hu; Andrei Thomas-Tikhonenko
Journal:  Mol Cell Biol       Date:  2018-10-15       Impact factor: 5.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.